Stay updated with breaking news from Interim Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch gezielte Einwirkung auf die Tumormikroumgebung (TME), gibt bekannt
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch gezielte Einwirkung auf die Tumormikroumgebung (TME), gibt
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell activationCytokine release syndrome observed and manageable, with low incidence of severe CRSManagement to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT SOUTH SAN FRANCISCO, C
Published: Mar 11, 2021 By Alex Keown Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” Rudolf Baumgartner, Chie...